Stocks
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -11.3 | -7.98 | -5.03 | -1.25 | -0.52 | -0.79 | ||
| Changes by years, y/y, % | +2 437% | -29% | -37% | -75% | -58% | +3.3% | |||
Allogene Therapeutics. EV/EBITDA
Allogene Therapeutics. EV/EBITDA, changes, %
Allogene Therapeutics (ALLO) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EV/EBITDA | ? | -0.86 | -0.94 | -0.47 | -0.61 | -1.73 | -0.79 | |
| Changes by years, y/y, % | -72% | -78% | -87% | -53% | +100% | |||
| Changes by quarters, q/q, % | -34% | +9% | -50% | +31% | +181% | |||
